Zenith Capital Corp. (ZHCLF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.59 Million USD | 19.24% |
| 2022 | -13.12 Million USD | -168169.85% |
| 2021 | -7797.00 USD | -12.79% |
| 2020 | -6913.00 USD | 28.21% |
| 2019 | -9630.00 USD | 14.98% |
| 2018 | -11.32 Thousand USD | 99.87% |
| 2017 | -8.54 Million USD | -23.2% |
| 2016 | -6.93 Million USD | 15.25% |
| 2015 | -8.18 Million USD | -3.39% |
| 2014 | -7.91 Million USD | 58.68% |
| 2013 | -19.16 Million USD | -80.36% |
| 2012 | -10.62 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.94 Million USD | -28.08% |
| 2023 Q4 | -1.51 Million USD | 37.9% |
| 2023 Q2 | -3.15 Million USD | 9.53% |
| 2023 Q1 | -3.48 Million USD | 55.38% |
| 2023 Q3 | -2.44 Million USD | 22.49% |
| 2022 Q3 | -1781.00 USD | 21.33% |
| 2022 Q1 | -1266.00 USD | 99.91% |
| 2022 FY | -13.12 Million USD | -168169.85% |
| 2022 Q2 | -2264.00 USD | -78.83% |
| 2022 Q4 | -7.8 Million USD | -438361.54% |
| 2021 Q4 | -1.45 Million USD | 26.92% |
| 2021 Q1 | -2.27 Million USD | -43.51% |
| 2021 Q2 | -2.08 Million USD | 8.3% |
| 2021 Q3 | -1.98 Million USD | 4.94% |
| 2021 FY | -7797.00 USD | -12.79% |
| 2020 Q2 | -1.81 Million USD | -3.71% |
| 2020 FY | -6913.00 USD | 28.21% |
| 2020 Q3 | -1.75 Million USD | 3.25% |
| 2020 Q4 | -1.58 Million USD | 9.78% |
| 2020 Q1 | -1.75 Million USD | 23.26% |
| 2019 Q1 | -1.73 Million USD | 58.34% |
| 2019 FY | -9630.00 USD | 14.98% |
| 2019 Q4 | -2.28 Million USD | 20.62% |
| 2019 Q3 | -2.87 Million USD | -5.0% |
| 2019 Q2 | -2.73 Million USD | -58.14% |
| 2018 Q4 | -4.15 Million USD | -60.44% |
| 2018 FY | -11.32 Thousand USD | 99.87% |
| 2018 Q3 | -2.59 Million USD | -5.33% |
| 2018 Q2 | -2.46 Million USD | -16.09% |
| 2018 Q1 | -2.11 Million USD | 24.02% |
| 2017 Q2 | -838 Thousand USD | 63.89% |
| 2017 Q3 | -2.59 Million USD | -210.14% |
| 2017 Q1 | -2.32 Million USD | 1.9% |
| 2017 FY | -8.54 Million USD | -23.2% |
| 2017 Q4 | -2.78 Million USD | -7.31% |
| 2016 FY | -6.93 Million USD | 15.25% |
| 2016 Q4 | -2.36 Million USD | -31.96% |
| 2016 Q3 | -1.79 Million USD | -5.35% |
| 2016 Q2 | -1.7 Million USD | -58.33% |
| 2016 Q1 | -1.07 Million USD | 46.14% |
| 2015 FY | -8.18 Million USD | -3.39% |
| 2015 Q1 | -2.04 Million USD | 16.94% |
| 2015 Q4 | -1.99 Million USD | -12.58% |
| 2015 Q3 | -1.77 Million USD | 25.19% |
| 2015 Q2 | -2.37 Million USD | -15.89% |
| 2014 Q4 | -2.46 Million USD | -900.81% |
| 2014 Q1 | -3.65 Million USD | 55.36% |
| 2014 FY | -7.91 Million USD | 58.68% |
| 2014 Q3 | -246 Thousand USD | 84.18% |
| 2014 Q2 | -1.55 Million USD | 57.43% |
| 2013 Q2 | -3.52 Million USD | -2.86% |
| 2013 Q3 | -4.02 Million USD | -14.01% |
| 2013 Q4 | -8.18 Million USD | -103.51% |
| 2013 Q1 | -3.42 Million USD | -5.77% |
| 2013 FY | -19.16 Million USD | -80.36% |
| 2012 FY | -10.62 Million USD | 0.0% |
| 2012 Q4 | -3.24 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 120.0% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1575.503% |
| Nascent Biotech, Inc. | -2.08 Million USD | -407.549% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2450.309% |
| Qrons Inc. | -789.34 Thousand USD | -1242.375% |
| Rebus Holdings, Inc. | -1.02 Million USD | -938.824% |
| Skye Bioscience, Inc. | -37.64 Million USD | 71.853% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 116.268% |
| Adynxx, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -693.452% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 83.073% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 33.239% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -51.744% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 85.865% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -61.129% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -3775.612% |
| SQZ Biotechnologies Company | -79.46 Million USD | 86.666% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -266.34% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -482.029% |
| Mesoblast Limited | -87.95 Million USD | 87.953% |
| Marizyme, Inc. | -65.34 Million USD | 83.785% |
| Genus plc | 7.9 Million USD | 234.127% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 2.715% |
| Pharming Group N.V. | -10.54 Million USD | -0.455% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -388.337% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -185.588% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -19.81% |
| ContraFect Corporation | -65.15 Million USD | 83.737% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -116.862% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -513.388% |
| IMV Inc. | -36.48 Million USD | 70.958% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -31.469% |
| MultiCell Technologies, Inc. | -380.07 USD | -2787807.491% |
| ONE Bio Corp. | 8.67 Million USD | 222.121% |
| Accustem Sciences Inc. | -3.74 Million USD | -182.83% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 79.502% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -736.218% |
| Q BioMed Inc. | -2.05 Million USD | -416.351% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -183.847% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -345.047% |
| Biomind Labs Inc. | -1.21 Million USD | -772.588% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 82.259% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -241.612% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -34.074% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -443.594% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -70653.205% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -82.148% |
| GB Sciences, Inc. | -1.36 Million USD | -678.158% |
| Alpha Cognition Inc. | -13.77 Million USD | 23.064% |
| HST Global, Inc. | -146.21 Thousand USD | -7147.11% |
| CSL Limited | 2.64 Billion USD | 100.401% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -503.839% |
| Halberd Corporation | -79.67 Thousand USD | -13198.86% |
| Enzolytics Inc. | -2.17 Million USD | -386.762% |
| Agentix Corp. | -1.37 Million USD | -671.061% |
| Resverlogix Corp. | -3.61 Million USD | -193.518% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -234.107% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 96.409% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 10912.245% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 253.02% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -166.701% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -250.15% |
| AVAX Technologies, Inc. | -6.41 Million USD | -65.21% |
| Genscript Biotech Corporation | -95.47 Million USD | 88.902% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -45489.88% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -155.576% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -17431.259% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -428.448% |
| Kadimastem Ltd | -3.3 Million USD | -220.373% |
| Helix BioMedix, Inc. | -1.05 Million USD | -903.355% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -177.455% |
| BioStem Technologies, Inc. | -8.48 Million USD | -24.909% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -2300.712% |
| LadRx Corporation | 400.44 Thousand USD | 2746.069% |
| Cell Source, Inc. | -5.32 Million USD | -99.128% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1135.263% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1135.263% |
| NovAccess Global Inc. | -4.76 Million USD | -122.176% |
| Affymax, Inc. | -14.42 Million USD | 26.539% |
| Itoco Inc. | -1.86 Million USD | -466.936% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -138.512% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -534.871% |
| Mobile Lads Corp. | -2.26 Million USD | -368.168% |
| CytoDyn Inc. | -49.84 Million USD | 78.74% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -13307.058% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -4544.781% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1025.403% |
| SYBLEU INC | -180.3 Thousand USD | -5776.742% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -557.02% |
| International Stem Cell Corporation | -131 Thousand USD | -7988.55% |
| Bioxytran, Inc. | -4.28 Million USD | -147.57% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -19423.88% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -318.773% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 77.958% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -401.23% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1256.918% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -234.47% |
| Neutra Corp. | -233.46 Thousand USD | -4438.582% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 47.78% |
| PureTech Health plc | -65.69 Million USD | 83.871% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 50.175% |
| IXICO plc | -1.17 Million USD | -799.491% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -6.739% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 81.452% |
| CSL Limited | 2.64 Billion USD | 100.401% |
| Cellectis S.A. | -103.17 Million USD | 89.73% |